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Endothelial cells (ECs) are a heterogeneous population that fulfills many physiological processes. ECs also actively
participate in both innate and adaptive immune responses. ECs are one of the first cell types to detect foreign
pathogens and endogenous metabolite-related danger signals in the bloodstream, in which ECs function as danger
signal sensors. Treatment with lipopolysaccharide activates ECs, causing the production of pro-inflammatory
cytokines and chemokines, which amplify the immune response by recruiting immune cells. Thus, ECs function as
immune/inflammation effectors and immune cell mobilizers. ECs also induce cytokine production by immune cells,
in which ECs function as immune regulators either by activating or suppressing immune cell function. In addition,
under certain conditions, ECs can serve as antigen presenting cells (antigen presenters) by expressing both MHC I
and II molecules and presenting endothelial antigens to T cells. These facts along with the new concept of
endothelial plasticity suggest that ECs are dynamic cells that respond to extracellular environmental changes and
play a meaningful role in immune system function. Based on these novel EC functions, we propose a new
paradigm that ECs are conditional innate immune cells. This paradigm provides a novel insight into the functions of
ECs in inflammatory/immune pathologies.
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Endothelial cells (ECs) form a single cell layer called the
endothelium, which lines the vasculature and lymphatic
systems forming a semi-permeable barrier between
blood or lymph within vessels and the surrounding tis-
sues. The endothelium is a highly specialized, dynamic,
disseminated organ with many essential functions in
physiological processes. In its entirety, the endothelium
is composed of 1 to 6 × 1013 ECs covering a surface area
of more than 1000 square meter [1]. ECs from different
vascular sites also have numerous variations in their ap-
pearance. Vascular ECs usually have a flattened squamous
structure, but they can also be cuboidal and have varying
thicknesses from less than 0.1 μm to 1 μm across the vas-
cular tree. Moreover, ECs among different tissues are het-
erogeneous with respect to their protein and surface
marker expressions [2,3]. In fact, different subsets of ECs* Correspondence: xfyang@temple.edu
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reproduction in any medium, provided the orcan be found within a single organ such as the liver [4].
The heterogeneity of ECs contributes to their diversity in
function at different vascular sites [5-7].
Besides serving as a physical barrier, ECs have a wide
array of functions which are characterized into three
major categories: trophic, tonic, and trafficking [8].
Under physiological conditions, ECs are involved in
the modulations of metabolic homeostasis (trophic
function), vascular hemodynamics (tonic function), vascu-
lar permeability, coagulation, and cell extravasation (traf-
ficking) [8]. In a quiescent state, ECs balance the release
of various vasodilating or vasoconstricting factors such as
nitric oxide, prostacyclins, and endothelin to maintain vas-
cular tone, blood pressure, and blood flow [9]. Further-
more, the endothelium is crucial in regulating coagulation,
utilizing both anti-coagulation and pro-coagulation mech-
anisms. Under standard physiological conditions ECs
express inhibitors of the tissue factor pathway and
thrombomodulin, which prevents the activation of
pro-coagulation molecules including factor X, throm-
bin, and fibrin. However, once the endothelium is injured,
the EC surface quickly transforms to a pro-coagulant state. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lation cascade [10]. In addition to coagulation, ECs have
an essential role in modulating vascular permeability. This
function regulates the ability of cells to move to and from
the circulatory system during inflammatory responses.
Under normal physiological conditions, endothelium basal
permeability only allows for the easy diffusion of solutes
such as glucose, ions, and other metabolites to underlying
cells. However, during states of acute and chronic inflam-
mation, endothelial permeability is increased, allowing for
additional trafficking of immune cells. Excessive or
prolonged increases in permeability, as seen in cases such
as chronic inflammation, can have deleterious effects
resulting in tissue edema. Endothelial permeability is me-
diated via two pathways; paracellular and transcellullar
[11,12]. The inability of ECs to adequately carry out these
or any other basal functions is referred to as endothelial
dysfunction, and is a hallmark of several cardiovascular
diseases.
In addition to the aforementioned physiological func-
tions, ECs also have important immunological functions.
Cells of the immune system function to defend against
invasive foreign pathogens and detrimental endogenous
materials. Cells of the innate immune system cells in-
clude neutrophils, monocytes, macrophages, dendritic
cells (DCs), Langerhans cell, natural killer (NK) cells, ba-
sophils, mast cells, and eosinophils, whereas cells of the
adaptive immune system are comprised of B, T and NKT
lymphocytes. The innate immune system mediates non-
specific immunity, thus its response is immediate and
antigen-independent. Innate immune cells patrol the
blood and are the first to sense foreign pathogens, acting
as a barrier to infections. Upon pathogen detection, cells
of the innate immune system produce cytokines and
chemokines which recruit phagocytes to the site of infec-
tion. Phagocytes, including neutrophils and macrophages,
engulf and destroy foreign pathogens via granules or lyso-
somes that contain proteolytic and hydrolytic enzymes.
On the other hand, the initiation of adaptive immunity
requires the interaction of innate immune cells with
cells of the adaptive immune system. Professional
antigen-presenting cells, such as macrophages, DCs,
and B cells, engulf pathogens and then process and
present peptide antigens to lymphocytes via major
histocompatibility complex (MHC) class I and class II
molecules. Although B cells can recognize and respond
to membrane-bound and non-membrane-associated anti-
gens, it has been suggested that membrane-associated an-
tigens are more essential for B cell activation than soluble
antigens in vivo [13]. Innate immune cells that patrol the
blood, such as DCs, are equipped with a series of
pathogen-associated molecular pattern receptors includ-
ing Toll-like receptors (TLRs) [14] and nucleotide-binding
oligomerization domain (NOD)-like receptors (NLRs)[15]. TLRs, NLRs, retinoic acid inducible gene 1 (RIG-I)-
like receptors (RLRs), absent in melanoma 2 (AIM2)—like
receptors (ALRs) and C-type lectin receptors (CLRs) are
pattern recognition receptors (PRRs), which can identify
pathogen-associated molecular patterns (PAMPs). These
receptors are part of the innate immune system and are
known to be expressed on immune cells as well as non-
immune cells [16]. PRRs are able to sense components of
exogenous microbes as well as harmful endogenous com-
ponents. In addition to detecting different pathogens and
secreting cytokines [17], DCs are also equipped with cyto-
kine and chemokine receptors, which allow DCs to differ-
entiate and mature in response to their environment [18].
Endothelial cells are sentinels of the innate
immune system
Due to their location, ECs are one of the first cells to
interact with microbial components in the circulation.
Therefore, it can be extrapolated that EC recognition
and response may be integral to early innate immune
system activation. In fact, like DCs, ECs are reported to ex-
press both TLRs and NLRs [19,20], as well as express che-
mokine receptors [21,22]. Specifically, ECs have been shown
to secrete the pro-inflammatory cytokine interleukin-8
(IL-8) in a NOD1-dependent manner in response to
microbial stimulation [23,24]. In addition, ECs have
been reported to express the NOD2 receptor, which
recognizes the bacterial peptidoglycan muramyl dipep-
tide [25]. Muramyl dipeptide can activate ECs, leading
to the upregulation of IL-6 secretion, which induces CD4+
T helper cell-17 (Th17) polarization while inhibiting CD4+
Th1 and Th2 responses [26].
Immune responsive ECs in healthy arteries express
low levels of TLR2 and TLR4, whereas inflamed endo-
thelium and endothelium of atherosclerotic lesions have
significant upregulation of TLR2 and TLR4 expression
[27]. Lipopolysaccharide (LPS) is a major component of
Gram-negative bacteria cell wall that has been shown to
induce EC responses such as the production of IL-1, IL-8,
and monocyte chemotactic protein-1 (MCP-1) via TLR4
[28-31]. Similarly, LPS, tumor necrosis factor-α (TNF-α),
and interferon-γ (IFN-γ) can induce TLR2 expression via
a NF-κB-dependent manner, highlighting the importance
of TLR2 in innate immunity and host defense against
Gram-positive cell wall components [32]. It should be
noted that ECs also express CD14 which is also a known
receptor for LPS [33]. TLR3, TLR7, and TLR8 are im-
portant in detecting viral RNA and activating innate
immune responses against viruses. Although TLR7 and
TLR8 are not detected in ECs, human umbilical vein
endothelial cells (HUVECs) do express TLR3. In fact,
ECs also express IFN-α, which is an important cyto-
kine in regulating innate immune responses against vi-
ruses and is shown to strongly induce TLR3 expression
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nizes viral and bacterial DNA [27,35].
Aside from the expression of PRRs, ECs also express
important downstream adaptor molecules for PRR sig-
naling including myeloid differentiation-2 (MD2) and mye-
loid differentiation primary-response protein 88 (MyD88).
MD2, also known as lymphocyte antigen 96 (Ly96), is a
protein associated with the extracellular domain of TLR-4
that is required for LPS signaling through TLR-4 [36,37].
Meanwhile, MyD88 is an important intracellular adaptor
molecule in the canonical TLR signaling cascade.
Under physiological conditions, ECs express the lectin-
like oxidized low density lipoprotein (oxLDL) receptor
(LOX-1) at low levels. Strong evidence has suggested a
pathological role of LOX-1 in atherosclerosis, a chronic
autoimmune inflammatory disease. ECs have been shown
to upregulate the expression of LOX-1 in response to
stimulation by oxLDL, pro-inflammatory cytokines, and
proatherogenic factors such as angiotensin II [38].
In addition to enhanced expression of LOX-1 by ECs,
oxLDL also induces endothelial activation-featured cell
surface adhesion molecule expression [39,40] and has
been shown to impair nitric oxide (NO) production in
ECs by increasing superoxide generation [41]. An add-
itional function of LOX-1 is the mediation of endothelial
phagocytosis of aged red blood cells and apoptotic cells
that express phosphatidylserine on the cell surface. It
should also be noted that this LOX-1-mediated phagocy-
totic activity can be inhibited by oxLDL. In addition, the
expression of phosphatidyleserine on the cell surface is
reported to have pro-coagulation activity. Thus, LOX-1
is important in endothelial-mediated vascular homeosta-
sis and coagulation prevention under physiological con-
ditions [42].
Endothelial cells are conditional antigen presenting cells
The adaptive immune response is triggered when innate
immunity fails to eliminate inflammatory stimuli resulting
in the progression of the inflammatory reaction from one
that is acute to one that is chronic. The endothelium par-
ticipates in chronic inflammation via interactions with
specialized effector cells and by acting as antigen present-
ing cells (APCs) [43]. Although ECs are not professional
APCs, their secondary role in antigen presentation has
been recognized [44,45].
The participation of ECs in antigen presentation was
first indicated with the discovery of both MHC class I
and class II molecule expression. MHC I is expressed by
all nucleated cells, with basal levels being detected in
ECs [46]. Unlike the expression of MHC I by all cell
types, MHC II expression is limited to APCs [47]. Pro-
fessional APCs ubiquitously express MHC II, while cells
such as ECs, which are not considered classic APC, can
induce MHC II expression [48]. Moreover, MHC IImolecules are also found to be basally expressed in the
microvasculature [49]. In response to stimulations such
as hydrogen peroxide and IFN-γ, ECs can upregulate the
expression of MHC I and induce the expression of MHC
II [46,48,50]. In addition, activated ECs also express
co-stimulators including 4-1BB ligand (4-1BBL), indu-
cible co-stimulator ligand (ICOSL), and OX40 ligand
(OX40L), which are involved in memory T cell formation,
activation, and survival [51,52]. Meanwhile, ECs treated
with IFN-γ effectively induce CD4+ and CD8+ memory
T cells to produce cytokines and proliferate [52].
In mice, sinusoidal ECs expressing MHC molecules
and co-stimulators B7-1 and B7-2 are found to have ef-
fective antigen presenting function in vitro [53]. B7-1
and B7-2, also known as CD80 and CD86, respectively,
are used by professional APC to provide co-stimulation
to T cells via interaction with T cell CD28. Furthermore,
the glomerular endothelium also expresses B7-1 and B7-2
co-stimulators in ischemia/reperfusion injury, an event
that inevitability occurs in organ transplantation. The
notion that ECs act as APCs in organ transplant is
highlighted in studies where endothelium MHC and
co-stimulator molecule expressions are shown to trig-
ger allogeneic and autoimmune responses by memory
T cells leading to allograft rejection [52,54,55].
ECs have also been shown to express and up-regulate
CD1d upon stimulation [56,57]. CD1d is an MHC class
I-like molecule expressed by APCs and non-hematopoietic
cells. Cells expressing CD1d present glycolipid antigen to
invariant natural killer T cells (iNKT) during infection
resulting in their activation [58]. Although ECs express
CD1d and may have the capacity to present antigen to
iNKT, evidence of this has yet to be obtained in vivo.
The aforementioned expressions of MHC molecules
and co-stimulators by ECs selectively regulate the migra-
tion of antigen-specific lymphocytes to sites of inflam-
mation [44]. One of the first studies to show that
antigen presentation by ECs influences T cell recruit-
ment was seen in the guinea pig experimental allergic
encephalomyelitis model. In this model, central nervous
system ECs were shown to increase Ia antigen presenta-
tion before inflammatory cell infiltration. Furthermore,
clinical signs were detected that suggest endothelial Ia
presentation is involved in T cell recruitment in the dis-
ease [59]. Other in vitro data showed that transendothelial
migration of antigen-specific T cells is enhanced across
ECs that express that specific antigen. The frequency of T
cells with antigen specificity for MHC class II-DR17 trans-
migrate across an endothelial monolayer that expresses
DR17 antigen at a fourfold higher rate than other migrat-
ing T cells [60]. In type I diabetes, ECs are shown to have
a capacity to process and present islet autoantigen glu-
tamic acid decarboxylase GAD65 to autoreactive T cells
and enhance the transmigration of GAD65-specific T-cells
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with MHC class I to activated insulin-specific CD8+ T
cells. This causes their infiltration into the pancreas, lead-
ing to beta cell destruction and the onset of diabetes [62].
Endothelium antigen recognition by T lymphocytes is also
shown to drive the recruitment and tissue infiltration
of T cells in vivo. In fact, T cell and EC interactions
were visualized in vivo by intravital microscopy. In a
study it was shown HY antigen (a male tissue specific
antigen) presentation by the endothelium enhanced
HY-specific CD8+ T cells transendothelial cell migra-
tion resulting in a large influx of T cells into tissues
[63]. It is also reported that the trafficking of antigen-
specific CD8+ T cell across the blood brain barrier into
the brain depends on cerebral endothelium expression of
MHC I. It was shown that antigen-specific CD8+ T cells
only infiltrated into the brain when their cognate anti-
gen was present. Moreover, when antibody against
MHC I was used, CD8+ T cell infiltration was signifi-
cantly reduced [64].
Antigen presentation is known to be one of the first
steps in initiating adaptive immunity; however, in par-
ticular circumstances antigen presentation can also in-
duce immune tolerance. Under physiological conditions,
MHC I antigen presentation by liver sinusoidal endothe-
lial cells (LSECs) leads to recruitment of antigen-specific
naïve CD8+ T cells and the induction of local tolerance
[65]. In addition, LSECs are shown to cross-present anti-
gen to CD8+ T cells at a relatively low concentration
compared to myeloid APCs, such as macrophages and
DCs. In fact, CD8+ T cells co-cultured with antigen-
presenting LSECs secrete IFNγ and IL-2; however, uponFigure 1 Endothelial cells are conditional innate immune cells. In thei
histocompatibility class I) molecules and PPRs (pattern-recognition recepto
the presence of inflammatory stimuli and risk factors in the bloodstream, e
coagulatory state to a pro-inflammatory and pro-coagulatory state. Endoth
response to these stimuli, endothelial cells express MHC II molecules which
cells can upregulate the expression of surface adhesion molecules that ind
endothelium and facilitate transmigration to underlying tissues. In addition
and chemokines which can modulate the activities of immune cells.re-stimulation, the ability to secrete IFNγ and IL-2 is
diminished. Furthermore, CD8+ T cells had impaired
cytokine expression with extended co-culture [66]. An
tigen-presenting LSECs also have the ability to prime
naïve CD4+ T cells but fail to induce T effector cell dif-
ferentiation as seen with priming by other APCs [67].
Instead, LSEC-primed naïve CD4+ T cells acquired
regulatory properties marked by suppression of naïve
CD4+ responder T cell proliferation in vitro and sup-
pression of inflammation in an ovalbumin (OVA)-specific
autoimmune hepatitis model [68].
Immune enhancing and immune suppressive roles of
endothelial cells
ECs can either have immune enhancing or suppressive
functions depending on their cytokine profile and their
interaction with other immune cells. Cytokines are small
signaling molecules, secreted by cells, which can modu-
late the behavior and properties of cells via autocrine,
paracrine, or endocrine mechanisms. Cytokines also func-
tion to regulate immune responses. The location of ECs
makes them one of the first targets of cytokines circulating
in the blood stream. It should be noted, however, ECs are
not merely targets of cytokines, they also have the capacity
to generate and secrete cytokines under certain circum-
stances (Figure 1, Table 1).
Various factors and stimuli, including cytokines, can in-
duce EC activation, a state of heightened responsiveness.
EC activation may be classified into two types, type I and
type II. Type I activation includes rapid responses that are
independent of new gene expression. These responses are
mediated by ligands binding to the extracellular domainsr quiescent state, endothelial cells express MHC I (Major
rs) which detect PAMPs (pathogen-associated molecular patterns). In
ndothelial cells transform from an anti-inflammatory and anti-
elial cells can detect inflammatory stimuli and risk factors via PRRs. In
present endothelial antigens to immune cells. Moreover, endothelial
uce the adhesion of immune cells, such as leukocytes, to the
, endothelial cells enhance the secretion of pro-inflammatory cytokines
Table 1 List of pro-inflammatory/anti-inflammatory
cytokines and chemokines as well as growth factors





IL-1α TNF-α HCAEC [69]







TNF-α, TCC HIMEC [70]
Basal MBEC [74]




IL-1β, TCC HIMEC [70]
Shear stress BAEC [75]
LPS HCAEC [76]
IL-3 Basal HUVEC, HIMEC [70]
IL-5 Basal HCAEC, HUVEC,
HPAEC
[69]
IL-6 TNF-α, LPS HCAEC [69,76]






IL-4 + IL-1β HUVEC [77]
Histamine HUVEC [78]
LPS HUVEC [79]
IL-4 or IFN-γ + TNF-α
or IL-1β
HUAEC [80]
TNF-α + IL-4, TNF-α + IFN-γ HSVEC [80]
TNF-α HPAEC [69]
TNF-α, IL-1β, IL-4, IFN-γ,
TCC
HIMEC [70]
Shear stress BAEC [75]
Basal, LPS MBEC [74]
IL-8 TNF-α, LPS HCAEC [69,76]




TNF-α, IL-1β,TCC HIMEC [70]
Oral viridian streptococci HSVEC [82]
IL-10 Basal MBEC [74]
IL-11 Basal, PMA HUVEC [70,83]
Basal HIMEC [70]
Basal, PMA HAEC [83]
G-CSF MM-LDL HAEC, RAEC [84]
Table 1 List of pro-inflammatory/anti-inflammatory
cytokines and chemokines as well as growth factors
produced by endothelial cells in response to
various stimuli (Continued)
GM-CSF TNF-α HCAEC, HPAEC [69]
TNF-α, IL-1β, TNF-α + IL-4 HUVEC [69,70,80]
TNF-α + IL-4 HUAEC, HSVEC [80]
TNF-α, IL-1β HIMEC [70]
MM-LDL HAEC, RAEC [84]
Basal, LPS MBEC [74]
MCP-1 IL-4+ IL-1β, IL-4 + LPS HUVEC [77]
(CCL2) LPC HUVEC [85]
LPS HCAEC [76]




RANTES TNF-α + IFN-γ HUVEC [86]
(CCL5) TNF-α + IFN-γ, IL-1β HMMEC [87]
TGF-β TNF-α, IL-1β HUVEC, HIMEC [70]
TNF-α TNF-α, IL-1β HUVEC, HIMEC [70]
Basal MBEC [74]
LPS HCAEC [76]
Cytokine/chemokine induction either on mRNA or protein level.
Basal: basal expression without stimulus; Human coronary artery endothelial
cell: HCAEC; Human umbilical vein endothelial cell: HUVEC; Human pulmonary
artery endothelial cell: HPAEC; human intestinal microvascular endothelial cell:
HIMEC; Gulten reactive T cell clones supernatant: TCC; phorbol 12-myristate
13-acetate: PMA; Human saphenous vein endothelial cell: HSVEC; Human
aortic endothelial cell: HAEC; Rabbit aortic endothelial cell: RAEC; Minimally
modified low density lipoprotein: MM-LDL; Bovine aortic endothelial cell:
BAEC; Lysophosphatidylcholine: LPC; Human mucosal microvascular
endothelial cell:HMMEC; Mouse brain endothelial cell: MBEC.
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and signal through the intracellular G-protein αq subunit.
Type II activation is a relatively slower response that de-
pends on new gene expression but delivers a more
sustained inflammatory response [88]. EC activation is in-
tegral in mediating a proper inflammatory response; how-
ever, prolonged activation can also lead to endothelial
inflammation and dysfunction which precede the develop-
ment of several vascular diseases. Once activated, ECs can
upregulate cell surface adhesion molecules and pro-
thrombotic molecules. Moreover, activated ECs can generate
and secrete pro-inflammatory cytokines and chemokines. In
their basal state, cultured ECs have detectable mRNA levels
of numerous pro-inflammatory and anti-inflammatory cyto-
kines including IL-3, IL-7, IL-8, IL-11, IL-15, TNF-α, and
transforming growth factor-β (TGF-β) [70]. However, the
expression of pro-inflammatory cytokines is marginal, pos-
sibly inhibited by basal production of NO which maintains
endothelium quiescence [89]. Meanwhile, in response to
pro-inflammatory stimuli such as hypoxia, infection, or
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chemokines [90].
Pro-inflammatory
The broad spectrum of pro-inflammatory cytokines and
chemokines expressed by ECs includes IL-1β, IL-3, IL-5,
IL-6, IL-8, IL-11, IL-15, growth-regulated oncogene α
(GRO-α, CXCL1), MCP-1(CCL2), RANTES(CCL5) , and
TNF-α [90,91]. These pro-inflammatory cytokines and
chemokines are important in potentiating inflammatory
responses by inducing cytokine secretion by other cells
and recruiting immune cells to the site of inflammation.
Cytokines IL-1 and TNF-α are particularly effective in
inciting the expression of pro-inflammatory genes in
various cells. In addition, IL-1 and TNF-α synergistically
promote the inflammatory process, especially when in-
duced by infections, trauma, ischemia, immune-activated
T cells, or toxins [92]. Moreover, in response to stimuli,
the endothelium is also capable of expressing various
growth factors including granulocyte colony-stimulating
factor (G-CSF), macrophage colony-stimulating factor
(M-CSF), granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF), platelet-derived growth factor (PDGF), vas-
cular endothelial growth factor (VEGF), and fibroblast
growth factors (FGF) [93]. These factors play a critical role
during wound healing, menstrual cycles, cancers, and vari-
ous ischemic and inflammatory diseases [94]. In addition,
colony-stimulating factors and growth factors produced
by the endothelium are important for hematopoiesis
which increases the number of immune cells in the circu-
lation during inflammation.
Aside from promoting inflammatory responses via
cytokine production, ECs also physically interact with
immune cells during the inflammatory process. ECs at
rest do not interact with leukocytes; however, during in-
flammation, activated ECs upregulate the expression of
adhesion molecules and chemokines [95]. Adhesion
molecules including P-selectin, E-selectin, vascular cell
adhesion molecule-1 (VCAM-1), and intercellular adhe-
sion molecule-1 (ICAM-1) are upregulated leading to
leukocyte transmigration across the endothelium to the
site of inflammation. Leukocytes are recruited to the
endothelium at the site of injury via a series of steps
called the leukocyte adhesion cascade. Adhesion mole-
cules and chemokines are important in mediating each
step of this cascade. Initially, chemokines from the endo-
thelium attract and activate leukocytes. Then, leukocytes
will tether to and roll on EC surface during the initial step
of extravasation during inflammation. Leukocytes will
then undergo activation leading to arrest and spreading
on the endothelium. While the tethering and rolling on
ECs are mediated by selectins, the arrest and spreading of
leukocytes are mediated by integrins [96]. Finally, medi-
ated by platelet endothelial cell adhesion molecule-1(PECAM-1, CD31) and ICAM-1, leukocytes will transmi-
grate between ECs to the underlying tissues.
Like the expression of MHC and co-stimulator mole-
cules which selectively regulate the influx of antigen-
specific cells to the site of injury, adhesion molecules
and chemokines also facilitate this function. The endo-
thelium expression of particular adhesion molecules and
chemokines changes when acute inflammation pro-
gresses into chronic inflammation, thus allowing for the
extravasation of different effector cells. The selective influx
of effector cells permits for the polarization of immune re-
sponses in adaptive immunity. During inflammation that is
dominated by Th1 cells, ECs preferentially express chemo-
kine (C-X-C motif) ligand 10 (CXCL10) and E-selectin
which favor the recruitment of Th1 cells [97]. Meanwhile,
ECs express chemokine (C-C motif) ligand 26 (CCL26)
and VCAM1 to favor recruitment of Th2 cells during an
immune response that is dominated by Th2 cells [98]. Fur-
thermore, ECs can secrete the chemokine GROα or MCP-
1 to attract neutrophils or monocytes respectively, during
an acute inflammatory process [99,100].
Besides regulating immune cell recruitment to specific
inflammation sites, ECs can also signal immune cells to
produce cytokines. This induction occurs not only through
endothelial cytokine signaling but also by direct physical
interactions. EC surface molecules such as lymphocyte
function-associated antigen (LFA)-3 and ICAM-1 have
been shown to signal and increase IL-2 and IL-4 produc-
tion by T cells. In addition, co-culture of ECs with activated
T cells enhanced IFN-γ production. It has also been shown
that T cells are more responsive to IL-12 stimulation in the
presence of EC co-culture [101]. Mechanistically, ECs have
been found to increase and prolong cytokine production
by T cells via OX40 signaling. Co-stimulation of OX40 is
shown to stabilize the mRNAs of IL-2, IL-3, and IFN-γ
[102]. These data suggest that ECs have co-stimulatory sig-
nals that are necessary for optimal T cell activation. EC
co-stimulation effectively triggers cytokine secretion
from naïve and memory CD4+ T cells; however, it should
be noted that co-stimulation does not seem to induce dif-
ferentiation of human naïve CD4+ T cells [103].
Preliminary work has also demonstrated the impact
of ECs on DC maturation. An anti-angiogenic cytokine
derived from ECs, vascular endothelial growth inhibi-
tor functions to suppress EC proliferation in a cell
cycle-dependent manner. Aside from its impact on
ECs, vascular endothelial growth inhibitor has also
been revealed to promote the maturation of mouse
DCs, which is an important step in the initiation of
adaptive immunity [104].
Anti-inflammatory
Besides pro-inflammatory cytokines, ECs can also pro-
duce anti-inflammatory cytokines such as IL-1 receptor
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anistically, anti-inflammatory cytokines can either block
the process initiated by pro-inflammatory cytokines or
suppress the progression of the inflammatory cascade.
For example, cytokines such as IL-4, IL-10, IL-13, and
TGF-β suppress the production of IL-1, TNF-α, and
other pro-inflammatory cytokines [92]. In fact, the bal-
ance between pro-inflammatory and anti-inflammatory
cytokines is believed to decide the result of inflammatory
disease progression. It has been postulated that the pro-
pensity for developing inflammatory diseases is determined
by the dominant expression of pro-inflammatory cytokines
or the inadequate expression of anti-inflammatory cyto-
kines. Examples include IL-10-deficient mice which de-
velop inflammatory bowel disease, TGF-β1 knockout mice
getting spontaneous inflammatory disease, and mice defi-
cient in IL-1ra obtaining a disease that is nearly identical to
rheumatoid arthritis [92].
Aside from aiding T cells in playing a pro-inflammatory
role in immune responses, ECs can also induce sup-
pressive immune function in T cells. Mouse ECs acti-
vated by IFN-γ and co-cultured with allogeneic CD4+
T cells were shown to induce the generation of CD4+
CD25+ FOXP3+ regulatory T cells. Further analysis of
this regulatory T cell population revealed the upregulation
of surface glucocorticoid-induced TNFR-related protein
(GITR) and intracellular cytotoxic T-Lymphocyte Antigen
4 (CTLA4), suggesting that these CD4+CD25+ FOXP3+
regulatory T cells were activated and could inhibit the pro-
liferation of alloreactive T cells [105]. Furthermore, it was
found that co-culture of regulatory T cells with ECs can
enhance the suppressive function of CD4+ CD25+
FOXP3+ regulatory T cells. Mechanistically, after con-
tact with ECs, regulatory T cells upregulate the expres-
sion of programmed death-1 receptor and increase the
production of anti-inflammatory cytokines IL-10 and
TGF-β [106].
Endothelial-derived microparticles
In addition to cellular mediators such as cytokine,
chemokines, and adhesion molecules, endothelial cells
also induce cellular signaling via microparticles. Micro-
particles are small plasma membrane-derived vesicles,
usually 0.1-1.5 μm in diameter, that are released by various
cell types during cell activation or apoptosis - a type of
programmed cell death [107]. Various factors are shown
to induce endothelial vesiculation (microparticle forma-
tion) in vitro, including TNF-α, IL-1β, thrombin, calcium
ionophore [108], and reactive oxygen species [109]. Endo-
thelial microparticles (EMPs) are also released in the ab-
sence of stimulation, and microparticles of various cellular
origins are detected in healthy individuals, suggesting that
microparticle formation is a physiological process. EMPs
are found to be increased in patients with variouscardiovascular related diseases, including acute coronary
syndrome, hypertension, and heart failure [110]. Further-
more, in patients with systemic lupus erythematosus, a
risk factor of cardiovascular disease, higher levels of EMPs
were found. In fact, after receiving immunosuppressive
treatments to control their inflammatory disease activity,
these patients were shown to have reduced EMPs levels
[111]. It should be noted that circulating EMPs are not
merely biomarkers of inflammatory diseases but also con-
tributes the pathological state.
Microparticles express surface antigens from their cells
of origin which allows for the identification of their
sources. Depending on the stimulus which triggers their
release, EMPs may contain endothelial proteins such as
ICAM-1, PECAM-1, ανβ3 integrin, and VE-Cadherin
[112]. Moreover, EMPs also have endothelial nuclear
materials such as microRNA, RNA, and DNA. It has
been shown that EMPs can induce intracellular signaling
via the transfer of these nuclear materials and proteins
to target cells [113]. EMPs are also found to have pro-
coagulant and pro-adhesive properties [108], which
promote coagulation and vascular inflammation. In
fact, increased levels of circulating EMPs were detected in
patients with diabetes. It was found that EMPs generated
by high glucose treated cells, but not control untreated
cells, induced vascular inflammation and endothelial dys-
function via activation of p38 by NADPH oxidase [114].
EMPs also induced inflammation in acute lung injury by
increasing pulmonary and systemic levels of IL-1β and
TNF-α. These elevated pro-inflammatory cytokine levels
were found to correlate with increased neutrophil recruit-
ment to the lungs [115]. EMPs were also found to induce
the maturation of plasmacytoid dendritic cells whereas
microparticles from T cells or platelet did not, under the
same conditions studied. Plasmacytoid dendritic cells ma-
tured by EMPs were shown to secrete pro-inflammatory
cytokines, IL-6 and IL-8, and induced proliferation of allo-
geneic naïve CD4+ T cells [116].
Endothelial cell plasticity
Naïve T cells can differentiate into different mature T cells
depending on the integration of a number of factors. Pre-
viously, it has been proposed that activated T cells are
committed to a specific terminal T cell phenotype. How-
ever, as our knowledge in the field advances, we have
come to realize that activated T cells are flexible in their
cytokine production in response to various stimuli. The
plasticity of T cell subsets allows for rapid immune system
response to various pathogens [117]. Similar to classic im-
mune cells, ECs were initially thought to be a terminally
differentiated cell type. Recently, however, the concept of
EC plasticity has gained recognition. During embryogen-
esis, ECs derived from the mesoderm, via vasculogenesis,
give rise to the early embryonic vasculature. Then through
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and forms new blood vessels. As the vasculature develops,
ECs become differentiated into either arterial or venous
specific cells. Notch signaling is crucial during this process,
while several transcription factors have been identified that
also play a role in this development [118]. Specifically,
Notch signaling is important in promoting EC differenti-
ation toward arterial cell differentiation suppressing venous
cell development. This is further supported by the fact that
chicken ovalbumin upstream promoter-transcription factor
II (COUP-TFII), an orphan nuclear receptor, suppresses
Notch signaling and thereby promotes venous cell differen-
tiation [119].
It has been well cited that blood ECs can be reprogramed
to lymphatic EC and vice versa via the activity of homeo-
box transcription factor Prox1 [120-122]. The lymphatic
vasculature works in concert with the blood vasculature in
maintaining fluid homeostasis by collecting fluid from
tissues and returning it to the blood supply. MoreTable 2 Comparison of endothelial cells and macrophages, pr
Endothelial cells
Cytokine secretion Pro-inflammatory cytokines
Anti-inflammatory cytokines
Phagocytic function Non-professional phagocytic cells
Phagocytosis of age blood cells and apoptotic cells
Antigen presentation Non-professional antigen presenting cells [45]
PAMPs and DAMPs
sensing





Pro-inflammatory Produce pro-inflammatory cytokines
Immune-enhancing Express adhesion molecules and chemokines to att
circulating leukocytes
Anti-inflammatory Express inhibitors of the tissue factor pathway and
thrombomodulin, which prevents the activation of
pro-coagulation pathwayImmunosuppression
Augment suppressive function of regulatory T cells
Migration Essential for vascular development and
angiogenesis [150]
Heterogeneity Within and among tissues, they may have differenc
in appearance and variation protein and surface
marker expressions
Plasticity Phenotypic change is dependent on environment
pathological conditionsimportantly, the lymphatic vasculature transports im-
mune cells such as APCs to the lymph nodes where
immune responses can be initiated. The mammalian
lymphatic vasculature is venous-derived as indicated
by lineage-tracing [123], suggesting that the existence
of a normal blood vascular network is a criterion for
the lymphatic vasculature. It has been proposed that
the plasticity of ECs via Prox1 regulation allows for the
rapid formation of blood ECs by dedifferentiation of
lymphatic ECs. Under conditions of rapid demand for
additional blood supply, the formation of new vessels
from bone marrow-derived endothelial progenitor cells
may not be quick enough. In order to satisfy this demand,
the dedifferentiation of nearby lymphatic EC could speed-
ily provide additional blood ECs [122]. Reciprocally, dur-
ing inflammatory processes where the rapid utilization of
immune cells requires the lymphatic system, blood ECs
that are infected with Kaposi’s sarcoma-associated herpes-




Professional phagocytic cells [135]
[42]
Professional antigen presenting cells [136]
r TLRs [138], NLRs [139]
C-type lectin receptors (CLRs) [140]
Scavenger receptor Class A Type I and II (SR-A I/II) [141]
Mannose receptors [143]
Dendritic cell-specific ICAM3-grabbing non-integrin
(DC-SIGN) [144]
Macrophage receptor with collagenous structure (MARCO) [145]
Complement receptor 3 (CR3) [146]
CD1 [147], CD14 [148], CD36 [149]
Classically activated macrophages [134]
ract Produce high levels of pro-inflammatory mediators
and cytokines
Regulatory macrophages [134]
Produce anti-inflammatory cytokine IL-10; limit
inflammation during later stages of immune
responses
Migration to sites of infection or injury in response
to pro-inflammatory stimuli and insults [151,152]
e Anatomical locations and functions determine
subpopulations
Surface marker expression overlaps between different
subsets [134]
and Phenotypic change is dependent on environment
and pathological conditions [134]
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of inflammatory cytokines to blood ECs has been shown
to have a similar effect [125].
In addition to differentiation into alternative EC lineage,
ECs may also be induced to have stem-cell like properties
via endothelial-mesenchymal transition (EndMT). During
EndMT, mature and progenitor ECs acquire a mesenchy-
mal phenotype that can give rise to other cell types
[126,127]. EndMT is crucial during embryonic develop-
ment. When the heart develops, some ECs that line the
endocardial cushion go through EndMT. Some of these
ECs remain vascular, while others become mesenchyme
and enter the underlying tissue to participate in the for-
mation of the heart valves and septa [128]. Mechanistic-
ally, TGF-β and Notch pathways have been shown to be
important in regulating endothelial plasticity [129]. The
role of EndMT in disease progression has been postulated
and specifically in cancer has been explored. It was found
that EndMT is a contributing source of cancer-associated
fibroblasts, cells that participate in tumor growth and me-
tastasis [130]. In addition to cancer, ECs are also found to
be a source of fibroblasts through EndMT. These cells
have a pathological impact by contributing to the fibrosis
of organs such as the kidney, lung, and heart [131-133].
Summary
ECs are a heterogeneous population that carries out
many essential physiological processes. Aside from these
basal functions, ECs also actively participate in both in-
nate and adaptive immunity. Due to their location, ECs
are one of the first cell types to detect foreign pathogens
and endogenous metabolite-related danger signals in the
bloodstream. Treatment with bacterial endotoxin such
as LPS activates ECs causing the production of pro-
inflammatory cytokines and chemokines, which amplify
the immune response by attracting and mediating the
extravasations of immune cells. Besides immune cell
trafficking, ECs also induce cytokine production in im-
mune cells. In addition, under certain conditions, ECs
can serve as antigen presenting cells (Table 2). In fact,
expressing both MHC I and II molecules, it has been
shown that recognition of endothelial antigens by T cells
expedites their infiltration in tissues. These facts along
with the new concept of endothelial plasticity suggest
that ECs are dynamic cells that respond to extracellular
environmental changes and play a meaningful role in
immune system function.
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